Schistosomiasis primarily affects the urogenital and intestinal systems. To effectively combat schistosomiasis, our company is committed to advancing the field of schistosomiasis diagnostics through cutting-edge technologies and tailored IVD solutions. By developing innovative IVD kits and compact diagnostic devices, we aim to address the complexity and diagnostic challenges of schistosomiasis pathogenesis and fundamentally change the detection and management of this infectious disease.
Introduction to Schistosomiasis
Schistosomiasis, an overlooked tropical illness, stems from parasitic flatworms belonging to the Schistosoma genus. Leveraging snails as intermediary hosts in their life cycle, these parasites transmit to humans through contaminated water exposure. With over 230 million global cases, schistosomiasis persists as a critical public health concern on a worldwide scale. The development of advanced diagnostic tools is critical to combating schistosomiasis and reducing its global impact.
Fig. 1 The life cycle of human schistosomiasis. (McManus, Donald P., et al., 2020)
Diagnostic Biomarkers for Schistosomiasis
Biomarkers such as antigens, antibodies, and DNA are essential for early detection, therapeutic monitoring, and disease management of schistosomiasis. Incorporating these biomarkers into schistosomiasis diagnostic strategies can improve the accuracy, sensitivity, and specificity of detection methods.
Antigens
Circulating cathodic antigen (CCA) is a glycoprotein released by adult schistosomes. Rapid diagnostic tests that detect CCA in urine have shown potential for diagnosing active Schistosoma infections, especially in areas with high disease prevalence.
Antibodies
Detection of antibodies to Schistosoma antigens in serum or plasma can indicate current or past infection. Enzyme-linked immunosorbent assay (ELISA) can detect the presence of antibodies in serum or plasma samples.
DNA
The use of DNA markers in the diagnosis of schistosomiasis offers new opportunities for sensitive and specific detection. PCR tests can identify schistosome species, quantify parasite numbers, and differentiate active from past infections.
IVD Kits for Schistosomiasis
In vitro diagnostic (IVD) kits provide a rapid, accurate, and cost-effective method to detect specific antigens or antibodies associated with Schistosoma infection. By rapidly identifying active infection, monitoring therapeutic response, and differentiating between acute and chronic cases, IVD kits can enhance therapeutic decision-making, facilitate timely intervention, and improve care outcomes.
| Kits |
Applications |
Detection Methods |
| Schistosoma IgG Antibody Test Kit |
Detection of IgG antibodies against Schistosoma in serum samples. |
ELISA |
| Schistosoma Rapid Test Kit |
Point-of-care testing (POCT) of circulating cathodic antigen (CCA) in urine. |
Lateral Flow Assay |
| Schistosoma DNA Detection Kit |
Testing for Schistosoma DNA in urine or stool samples. |
PCR, LAMP |
Our Services
Within our company, our primary emphasis is on crafting IVD solutions specifically designed for combating schistosomiasis. We are dedicated to creating state-of-the-art antigen, antibody, and DNA test kits that precisely detect this feared infectious disease. Through the innovation of diagnostic devices, our objective is to streamline the process of diagnosis and enhance the efficient therapeutics of schistosomiasis.
Acknowledging the significance of point-of-care testing (POCT) in areas with limited resources, our researchers specialize in creating swift diagnostic tests for immediate schistosomiasis detection on location. Our companion diagnostic development services concentrate on integrating diagnostic tests with precise therapeutics to facilitate personalized therapeutic solutions for managing schistosomiasis.
If you are interested in our services, please don't hesitate to reach out to us for further information and pricing details on the services we offer.
Reference
- McManus, Donald P., et al. "Schistosomiasis—from immunopathology to vaccines." Seminars in immunopathology. Vol. 42. Springer Berlin Heidelberg, 2020.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
